AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15567788
Drug: Intravenous propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous propofol combined with fentanyl (group B)
Trial: 10786107
Drug: Subcutaneous suture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous suture (group 1)
Trial: 10786107
Drug: No subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No subcutaneous suture (group 2)
Trial: 9378168
Drug: Carboplatin (C)
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin (C) 400 mg/m2 every three weeks
Trial: 9378168
Drug: Carboplatin 350
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin 350 mg/m2, ifosfamide (I) 5 g/m2 with mesna, vincristine (V) 1.4 mg/m2, and bleomycin (B) 30 mg every ten days (CIVB arm)
Trial: 8638801
Drug: Vecuronium 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.1 mg/kg
Trial: 3475430
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (hydrochlorothiazide + triamterene) with methyldopa if blood pressure remained elevated
Trial: 18604321
Drug: Standard nutritional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard nutritional supplement
Trial: 6639916
Drug: Both supplements
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both supplements
Trial: 31538149
Drug: Lidocaine 2%
RxNorm normalized name: LIDOCAINE 2% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 2% prior to 0.5 mg/kg midazolam (group B)
Trial: 31538149
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg midazolam (group A)
Trial: 31538149
Drug: Saline 0.9%
RxNorm normalized name: CVS Saline 0.9% Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 0.9% (placebo) with 0.5 mg/kg midazolam (group C)
Trial: 27696490
Drug: Propofol (high,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (high, 3 μg/mL; medium, 1.5 μg/mL; low, 0.5 μg/mL; or no drug) and Remifentanil (high, 6 or 8 ng/mL; medium, 4 ng/mL; low, 2 ng/mL; or no drug)
Trial: 19673337
Drug: Chemotherapy (FOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (FOLFOX regimen) combined with Shenqi Fuzheng Injection (SFI)
Trial: 19673337
Drug: Chemotherapy (FOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (FOLFOX regimen) alone
Trial: 10920901
Drug: ProMACE‐CytaBOM (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ProMACE‐CytaBOM (treatment group)
Trial: 29729655
Drug: Sexual risk
RxNorm normalized name: Hep B, adolescent/high risk infant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sexual risk reduction intervention (details on dosage and duration not available)
Trial: 25041811
Drug: ABT-384 single-dose
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-384 single-dose (1, 8, 20, 50, 120 and 240 mg)
Trial: 22951426
Drug: Oral cefditoren
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cefditoren pivoxil 400mg once daily
Trial: 18028385
Drug: Combined spinal-epidural
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined spinal-epidural analgesia with subarachnoid morphine, bupivacaine, and fentanyl (MBF group)
Trial: 18028385
Drug: Morphine and
RxNorm normalized name: morphine and antispasmodics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine and bupivacaine (MB group)
Trial: 18028385
Drug: Morphine (M
RxNorm normalized name: Product containing morphine (medicinal product)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (M group)
Trial: 10685817
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin A (BTX‐A) 100 units diluted in 1 ml saline, injected at five trigger points (0.2 ml each) via a 30 gauge needle.
Trial: 10685817
Drug: Saline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (1 ml) as placebo control, injected at five trigger points.
Trial: 18355366
Drug: Low-dose HT
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose HT (1 mg 17 beta‐estradiol + 0.5 mg norethisterone acetate)
Trial: 18355366
Drug: Conventional-dose HT
RxNorm normalized name: 5-HT
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional-dose HT (2 mg 17 beta‐estradiol and 1 mg NETA)
Trial: 17156824
Drug: Raloxifene (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene (60 mg)
Trial: 12767572
Drug: Transdermal estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal estrogen replacement therapy (TTS 50 twice‐weekly)
Trial: 10488988
Drug: Ephedrine 0.12
RxNorm normalized name: Primatene with ephedrine 0.125 MG/ACTUAT Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine 0.12 mg
Trial: 10488988
Drug: Ephedrine 0.24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine 0.24 mg
Trial: 8945044
Drug: Model 1400T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Model 1400T lead (impregnated with steroid)
Trial: 8945044
Drug: Model 1401T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Model 1401T lead (not impregnated with steroid)
Trial: 27384580
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid supplement (SUPP)
Trial: 24782447
Drug: Vestibular suppressant
RxNorm normalized name: Buckley's Cough Suppressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vestibular suppressant (dimenhydrinate 50 mg per day)
Trial: 19114222
Drug: Supportive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive therapy (control, n=20)
Trial: 14668570
Drug: Morning dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning dosing with cilnidipine
Trial: 14668570
Drug: Bedtime dosing
RxNorm normalized name: Buckley's Bedtime Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedtime dosing with cilnidipine
Trial: 12482110
Drug: Pulsed estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed estrogen therapy (Aerodiol®)
Trial: 339940
Drug: Maintenance chemotherapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance chemotherapy plus immunotherapy with BCG and irradiated allogeneic blast cells
Trial: 6944146
Drug: Maintenance chemotherapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance chemotherapy alone
Trial: 23386704
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin D (4000 IU/day)
Trial: 23386704
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (High-dose vitamin D and Placebo)
Trial: 8066558
Drug: Auranofin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auranofin (3 mg orally twice a day)
Trial: 3378222
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of cis-diamminedichloroplatinum(II) at 30 mg/m2/day for 5 days
Trial: 3378222
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of cis-diamminedichloroplatinum(II)
Trial: 27824882
Drug: HIV self-testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV self-testing (HIVST) group; participants received two oral-fluid-based HIV test kits and were encouraged to distribute one to their male partner or use both for testing as a couple.
Trial: 27824882
Drug: HIV self-testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV self-testing (HIVST) group; participants received two oral-fluid-based HIV test kits.
Trial: 11732148
Drug: mefloquine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mefloquine (10 mg/kg followed by 5 mg/kg at 6 h)
Trial: 7963156
Drug: Prednisone (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (single oral dose)
Trial: 18344552
Drug: levobupivacaine 0.175%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levobupivacaine 0.175% with 0.5 mg kg(‐1) S(+)‐ketamine (Group 2)
Trial: 18344552
Drug: levobupivacaine 0.15%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levobupivacaine 0.15% with 0.5 mg kg(‐1) S(+)‐ketamine (Group 1)
Trial: 12390056
Drug: Pravastatin 20
RxNorm normalized name: pravastatin 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 20 mg daily
Trial: 9126664
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg and 20 mg
Trial: 23466100
Drug: Pravastatin 20
RxNorm normalized name: pravastatin 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 20 mg and 40 mg
Trial: 22578664
Drug: Humor therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humor therapy with professional performers (ElderClowns) and trained facility staff (LaughterBosses) for a minimum of nine two-hour sessions over 12 weeks.
Trial: 22578664
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (control group) with no formal humor therapy.
Trial: 16525815
Drug: 24 mg
RxNorm normalized name: uracil 224 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 mg potassium bromide daily for 20 weeks
Trial: 16525815
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg potassium bromide daily for 20 weeks
Trial: 12720588
Drug: 3.5 g
RxNorm normalized name: Calcium 760 MG/3.5 GM Oral Granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5 g ALNA/d
Trial: 12720588
Drug: 0.44 g
RxNorm normalized name: MENTHOL 0.44 g in 100 g / ZINC OXIDE 21 g in 100 g TOPICAL OINTMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.44 g EPA+DHA/d
Trial: 12720588
Drug: 0.94 g
RxNorm normalized name: BUPHENYL 0.94 GM/GM Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.94 g EPA+DHA/d
Trial: 12720588
Drug: 1.9 g
RxNorm normalized name: aluminum phosphate 61.9 GM per 100 GM Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.9 g EPA+DHA/d
Trial: 8322695
Drug: Nifedipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (10 mg sublingually)
Trial: 31869478
Drug: Child Life
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Child Life preparation (minimum 15 minutes)
Trial: 25572038
Drug: Tryptophan-rich dietary
RxNorm normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tryptophan-rich dietary supplement from egg protein hydrolysate (0.5 g twice per day for 19 days)
Trial: 25572038
Drug: Placebo (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.5 g twice per day for 19 days)
Trial: 20600734
Drug: Plain drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain drug tablets (FMT)
Trial: 10857066
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (casting)
Trial: 9165546
Drug: Standard fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard fixed dose of 500 mg/day of oral zidovudine
Trial: 9165546
Drug: Concentration-controlled regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentration-controlled regimen of oral zidovudine
Trial: 1587194
Drug: Ranitidine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (mean 2150 mg/day, range 1200-3000 mg/day)
Trial: 1587194
Drug: Omeprazole (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (mean 33 mg/day, range 20-60 mg/day)
Trial: 2422479
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg sulphinpyrazone (SP)
Trial: 2422479
Drug: 880 mg
RxNorm normalized name: calcium carbonate 1880 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 880 mg acetylsalicylic acid (ASA)
Trial: 30833170
Drug: Semaglutide 1·0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semaglutide 1·0 mg
Trial: 31540617
Drug: Integrated Stepped
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Integrated Stepped Alcohol Treatment (ISAT)
Trial: 21955862
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (100 mg/day losartan after 40 mg/d enalapril for 4 months)
Trial: 14744276
Drug: High-dose eptifibatide
RxNorm normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose eptifibatide (two 180-microg/kg single-dose boluses before CAS, then a 2.0-microg/kg/min infusion for 20-24 hours)
Trial: 27520989
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical therapy (control group)
Trial: 8417172
Drug: Ribavirin 600
RxNorm normalized name: ribavirin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribavirin 600 mg or 800 mg for 24 weeks
Trial: 28923084
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy alone
Trial: 31870421
Drug: Tailored psychological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored psychological intervention (access to psychological treatment)
Trial: 19141765
Drug: Standard DHA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard DHA in infants born weighing less than 1250 g
Trial: 19141765
Drug: High-DHA diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-DHA diet in infants born weighing at least 1250 g
Trial: 19141765
Drug: Standard DHA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard DHA in infants born weighing at least 1250 g
Trial: 2968769
Drug: Salbutamol 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol 0.3 mg (SAL)
Trial: 2968769
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Salbutamol 0.3 mg and Disodium Cromoglycate 3 mg (SAL + DSCG)
Trial: 2968769
Drug: Disodium Cromoglycate
RxNorm normalized name: Disodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium Cromoglycate 3 mg (DSCG)
Trial: 12830444
Drug: Daily HD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily HD
Trial: 15328635
Drug: Intraoperative application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative application of 50 mg 5‐FU (Group A)
Trial: 15328635
Drug: Postoperative subconjunctival
RxNorm normalized name: lincomycin
DrugBank: Lincomycin (DB01627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative subconjunctival injections of 5 mg 5‐FU (Group B)
Trial: 15328635
Drug: Intra and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra and postoperative administration of 5‐FU (Group C)
Trial: 29781394
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy with Relaxation (CBT + R)
Trial: 28549015
Drug: Early oral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early oral feeding (EOF) on the first postoperative day
Trial: 28549015
Drug: Late oral
RxNorm normalized name: Adalate Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late oral feeding (LOF) 7 days after surgery
Trial: 28549015
Drug: Late oral
RxNorm normalized name: Adalate Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late oral feeding (LOF)
Trial: 25997842
Drug: Self-distancing (exemplar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-distancing (exemplar perspective, e.g., Batman)
Trial: 15664716
Drug: 15 mg/70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/70 kg d-amphetamine
Trial: 15664716
Drug: 7.5 mg/70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg/70 kg d-amphetamine
Trial: 15664716
Drug: 0 mg/70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg/70 kg (placebo)
Trial: 7976644
Drug: Morphine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (mean rate 2.3 mg/h, range 0‐4 mg/h)
Trial: 7976644
Drug: Midazolam (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (mean rate 2.8 mg/h, range 0‐5 mg/h)
Trial: 1095246
Drug: Intranasal beclomethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal beclomethasone dipropionate aerosol (400 mug/day)
Trial: 28051240
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy using azithromycin and bronchodilators or glucocorticoid
Trial: 15837236
Drug: ACAM2000 (highest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACAM2000 (highest dose)
Trial: 12888057
Drug: Control eyes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control eyes (conventional LASIK treatment)
Trial: 10454950
Drug: Sulfonylureas, Metformin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfonylureas, Metformin, or Insulin
Trial: 6350090
Drug: Propafenone (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone (900 mg/day)
Trial: 17882923
Drug: Mometasone nasal
RxNorm normalized name: mometasone nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mometasone nasal spray
Trial: 16280286
Drug: Irbesartan/HCTZ (150/12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan/HCTZ (150/12.5 mg)
Trial: 16280286
Drug: Valsartan/HCTZ (80/12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan/HCTZ (80/12.5 mg)
Trial: 28407625
Drug: Mapracorat 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mapracorat 0.1% ointment
Trial: 8929242
Drug: Reference drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference drugs
Trial: 19780001
Drug: Botulinum toxin‐A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin‐A injection (25 U, 0.5 ml, once)
Trial: 19780001
Drug: Lidocaine injection
RxNorm normalized name: lidocaine Injection
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine injection (2 ml, 20 mg, 1% lidocaine, twice a week for one month)
Trial: 19780001
Drug: Laser treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser treatments (20 sessions)
Trial: 11565402
Drug: Magnet-on group
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnet-on group (active treatment)
Trial: 31825248
Drug: SAR341402 insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAR341402 insulin aspart
Trial: 31223099
Drug: Fast infusion
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast infusion (1 h) of Zn (100 μmol)
Trial: 31223099
Drug: Slow infusion
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow infusion (10 h) of Se (1 μmol)
Trial: 31223099
Drug: Fast infusion
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast infusion (1 h) of Cr (200 nmol)
Trial: 31223099
Drug: Slow infusion
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow infusion (10 h) of Cr (200 nmol)
Trial: 31223099
Drug: Fast infusion
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast infusion (1 h) of Cu (8 μmol)
Trial: 31223099
Drug: Slow infusion
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow infusion (10 h) of Cu (8 μmol)
Trial: 31223099
Drug: Fast infusion
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast infusion (1 h) of Fe (20 μmol)
Trial: 31223099
Drug: Slow infusion
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow infusion (10 h) of Fe (20 μmol)
Trial: 31725351
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg every 3 weeks for up to 2 years
Trial: 25100336
Drug: 80 kVp,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 kVp, 2.2 pitch, 20 ml of contrast medium and sinogram affirmed iterative reconstruction
Trial: 9113175
Drug: bupivacaine 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine 12.5 mg + 10 micrograms fentanyl subarachnoidally
Trial: 9113175
Drug: bupivacaine 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine 12.5 mg + saline subarachnoidally
Trial: 9113175
Drug: bupivacaine 100
RxNorm normalized name: BUPivacaine 100 mg parenteral implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine 100 mg + saline epidurally
Trial: 3301785
Drug: Colistin inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colistin inhalation (1 million units twice daily for three months)
Trial: 3301785
Drug: Placebo inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhalation (isotonic saline)
Trial: 3301785
Drug: Colistin inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colistin inhalation